Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Effects of clopidogrel and clarithromycin on the oral disposition of sibutramine in healthy subjects
1. Plasma concentrations of sibutramine and its two active metabolites after single oral dose of sibutramine were determined in Korean healthy male subjects with different CYP2B6 genotypes (CYP2B6*1/*1, *1/*6 and *6/*6), either alone or after four-day pretreatment with clopidogrel or clarithromycin.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| sibutramine-clopidogrel | Active Comparator | sibutramine-clopidogrel |
|
| sibutramine-clarithromycin | Active Comparator | sibutramine-clarithromycin |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Sibutramine-clopidogrel | Drug | Sibutramine-clopidogrel |
| |
| Measure | Description | Time Frame |
|---|---|---|
| effects of clopidogrel and clarithromycin on the disposition of sibutramine | the effects of clopidogrel and clarithromycin on the disposition of sibutramine and its two active metabolites M1 and M2 in vivo in relation to CYP2B6*6 genetic polymorphism have been evaluated in Korean healthy subjects. | one year |
Not provided
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| JaeGook Shin, MD,PhD | Inje University | Principal Investigator |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| sibutramine-Clarithromycin |
| Drug |
sibutramine-Clarithromycin |
|